TAO Synergies operates a diversified business combining cryptocurrency treasury management with digital media. The company acquires and stakes TAO tokens from the Bittensor decentralized network for artificial intelligence, generating staking rewards through third-party validators and custodians, while managing the associated risks of variable fees, slashing penalties, and protocol dependencies. The company also operates The TAO Daily, an online news publication and data platform covering the Bittensor ecosystem and digital asset industry that generates revenue through advertising, though this creates potential conflicts of interest given the company's substantial TAO holdings. Previously focused on biopharmaceutical development, particularly Bryostatin-1 for Alzheimer's disease, the company has shifted strategic emphasis toward cryptocurrency treasury strategies while exploring alternatives for its legacy drug candidate.